Implementing chimeric antigen receptor T-cell therapy in practice
You must score at least 70% in this module to pass. Ensure you have read ‘Implementing chimeric antigen receptor T-cell therapy in practice’ before attempting to complete the module.
This module can be taken up to three times. Once you have passed, you can view the correct answers and download a certificate as a record of your learning.
Additional CPD modules are available in the ‘My CPD’ section of your account.
0 of 15 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 15 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Which of the following groups of medicines are classed as advanced therapy medicinal products?CorrectIncorrect
Tisagenlecleucel and axicabtagene ciloleucel are the two chimeric antigen receptor T-cell (CAR-T cell) treatments licensed in the UK. They can both be used to treat relapsed/refractory diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Which of the following correctly describes the other licensed indication?CorrectIncorrect
How does a CAR-T cell therapy exert its action?CorrectIncorrect
Doctors, pharmacists and nurses are involved in providing clinical CAR-T cell therapy to patients. Which other setting/discipline is integral to the delivery of CAR-T therapy?CorrectIncorrect
Why is storage and handling of a CAR-T cell therapy best undertaken by stem cell laboratory staff?CorrectIncorrect
Which of the following tasks is undertaken by staff skilled in cellular handling?CorrectIncorrect
Which of the following clinical trials was pivotal in gaining regulatory approval for CAR-T cells?CorrectIncorrect
What is apheresis?CorrectIncorrect
What are the storage conditions for frozen CAR-T cell therapy?CorrectIncorrect
CAR-T cell therapy can cause several toxicities. Which of the following is characteristic of immune effector cell associated neurotoxicity (ICANS)?CorrectIncorrect
Several medicines can be used to aid treatment of cytokine release syndrome (CRS). Which of the following medicines is licensed for this indication?CorrectIncorrect
ICANS can manifest in many ways. Which of these side effects does not necessarily represent neurotoxicity in every case?CorrectIncorrect
The treatment of ICANS involves input from a neurologist and, where appropriate, early transfer to the intensive care unit for monitoring. Which of the following medications can be used to treat one of the symptoms of ICANS?CorrectIncorrect
What dose of tocilizumab is used to treat CRS in adults?CorrectIncorrect
How could CAR-T cell therapy be relevant to a community pharmacist?CorrectIncorrect